Anti-Thymocyte Globulin and Etanercept in Treating Patients With Myelodysplastic Syndromes

Completed · Phase 2

Conditions studied: Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases

In brief

RATIONALE: Biological therapies, such as anti-thymocyte globulin and etanercept, may stimulate the immune system in different ways and stop cancer cells from growing. Giving anti-thymocyte globulin together with etanercept may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving anti-thymocyte globulin together with etanercept works in treating patients with myelodysplastic syndromes.

Key facts

Study ID

NCT00217386

Run by

Fred Hutchinson Cancer Center

People needed

30

Starts

2004-03-01

Last updated by the study team

2010-09-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• St. Joseph Cancer Center — Bellingham, Washington, United States
• Olympic Medical Center — Port Angeles, Washington, United States
• Seattle Cancer Care Alliance — Seattle, Washington, United States
• Fred Hutchinson Cancer Research Center — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.